Covetrus (CVET) Stock Price
Covetrus Price
Revenue has compounded at 7.4% per year over the past 6 years to 4.58 B USD. Earnings per share have grown at 19.8% per year over the last 2 years. Covetrus's net margin stands at -1.2%, down from 1.8% several years earlier.
Covetrus stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Covetrus over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Covetrus stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Covetrus's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Covetrus Price |
|---|
Covetrus Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Covetrus Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.98 | 3.35 | 3.58 | 3.78 | 3.98 | 4.34 | 4.58 | 4.80 | 5.09 | 5.56 | 5.79 | 6.14 |
| – | 12.59 | 6.74 | 5.53 | 5.27 | 9.13 | 5.44 | 4.85 | 6.00 | 9.32 | 4.10 | 6.17 |
| 17.80 | 18.46 | 18.22 | 18.11 | 18.84 | 18.39 | 18.75 | 18.75 | 18.75 | 18.75 | 18.75 | 18.75 |
| 0.53 | 0.62 | 0.65 | 0.68 | 0.75 | 0.80 | 0.86 | 0.90 | 0.95 | 1.04 | 1.09 | 1.15 |
| 103.00 | 123.00 | 135.00 | 137.00 | -997.00 | -69.00 | -22.00 | 239.00 | 274.00 | 301.00 | 332.00 | 372.00 |
| 3.46 | 3.67 | 3.77 | 3.63 | -25.08 | -1.59 | -0.48 | 4.98 | 5.39 | 5.41 | 5.74 | 6.05 |
| 0.06 | 0.07 | 0.06 | 0.10 | -1.02 | -0.02 | -0.05 | 0.15 | 0.18 | 0.19 | 0.21 | 0.24 |
| – | 16.67 | -8.57 | 56.25 | -1,119.00 | -98.14 | 184.21 | -381.48 | 15.79 | 9.66 | 10.88 | 13.08 |
| 137.00 | 72.00 | 72.00 | 72.00 | 107.00 | 118.00 | 137.00 | 137.00 | 137.00 | 137.00 | 137.00 | 137.00 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Covetrus generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Covetrus retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Covetrus's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Covetrus has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Covetrus's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Covetrus stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Covetrus Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Covetrus business model & stock analysis
Covetrus SWOT Analysis
Strengths
1. Market Leader: Covetrus Inc is one of the leading companies in the animal health technology and services industry, enjoying a significant market share.
2. Global Presence: The company operates in multiple countries, allowing it to reach a wide customer base worldwide.
Weaknesses
1. Dependency on Veterinary Practices: Covetrus Inc heavily relies on partnerships with veterinary practices for its revenue, making it susceptible to changes in their business models or declining demand.
2. Limited Product Portfolio: The company's product offerings are primarily focused on animal health technology and services, which may restrict its growth potential compared to companies with more diversified portfolios.
Opportunities
1. Growing Pet Industry: The increasing pet ownership and demand for related products and services present an opportunity for Covetrus Inc to expand its customer base and revenue.
2. Technological Advancements: Embracing emerging technologies in the animal health sector, such as telemedicine and digital healthcare solutions, can help Covetrus Inc enhance its offerings and stay ahead of competitors.
Threats
1. Intense Competition: The animal health technology and services industry is competitive, with the presence of established players and new entrants. Covetrus Inc needs to continually innovate and differentiate itself to maintain a competitive edge.
2. Regulatory Challenges: Compliance with regulatory requirements in various markets can pose challenges for Covetrus Inc, requiring significant investments and resources.
Covetrus Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Covetrus Segments
Covetrus Revenue by Segment
3 Years
5 Years
Max
Details
Covetrus Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Covetrus historical P/E ratio, EBIT multiple, and P/S ratio
Covetrus annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Covetrus shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Covetrus Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/2/2023 | 0.30USD | - | 1.31 BUSD | - | 2023 Q2 |
| 5/3/2023 | 0.28USD | - | 1.23 BUSD | - | 2023 Q1 |
| 2/22/2023 | 0.29USD | - | 1.24 BUSD | - | 2022 Q4 |
| 11/29/2022 | 0.27USD | - | 1.26 BUSD | - | 2022 Q3 |
| 8/4/2022 | 0.26USD | - | 1.24 BUSD | - | 2022 Q2 |
| 5/5/2022 | 0.23USD | - | 1.16 BUSD | - | 2022 Q1 |
| 2/24/2022 | 0.25USD | - | 1.15 BUSD | - | 2021 Q4 |
| 11/4/2021 | 0.23USD | - | 1.18 BUSD | - | 2021 Q3 |
| 8/5/2021 | 0.24USD | - | 1.13 BUSD | - | 2021 Q2 |
| 5/6/2021 | 0.17USD | - | 1.10 BUSD | - | 2021 Q1 |
Covetrus shareholder structure
| % | Name |
|---|---|
24.62212% | |
11.54392% | |
8.50921% | |
6.11161% | |
2.83096% | |
2.25156% |
Covetrus Beneficial Ownership Filings (SEC 13D/G)
Covetrus Executives and Management Board
21 members · avg. age 59 · 33 % women
Mr. Benjamin Wolin (47)
President, Chief Executive Officer, Director · since 2019
6.52 M USD
Management
Mr. Matthew Malenfant (60)
Chief Commercial Officer
Mr. Matthew Foulston (58)
Chief Financial Officer, Executive Vice President
Ms. Georgina Wraight (47)
Executive Vice President, President - Global Technology Solutions
Mr. Dustin Finer (52)
Chief Administrative Officer
Mr. Cesar Franca
President - Global Proprietary Brands
Mr. Anthony Providenti (54)
Executive Vice President - Corporate Development
Board of Directors
Mr. Philip Laskawy (80)
Independent Chairman of the Board
Mr. Edward Mcnamara (57)
Independent Director
Ms. Sandra Helton (72)
Independent Director
Ms. Deborah Ellinger (63)
Independent Director
Ms. Sharon Wienbar (60)
Independent Director
Mr. Mark Manoff (65)
Independent Director
Frequently asked questions about Covetrus
The business model of Covetrus Inc is to provide technology-enabled services and solutions for the veterinary market. As a leading global animal health technology and services company, Covetrus offers a comprehensive suite of software, pharmacy, and supply chain solutions for veterinary practices, clinics, and hospitals. By harnessing the power of technology, Covetrus aims to enhance patient care, improve practice efficiency, and streamline the veterinary supply chain. With a strong focus on innovation and customer-centric offerings, Covetrus continues to empower veterinary professionals with advanced tools and resources to deliver quality care to animals worldwide.
Covetrus Inc is primarily active in the animal health industry. With its comprehensive range of products, technologies, and services, Covetrus aims to improve the health and well-being of animals worldwide. Serving both veterinary practices and pet owners, Covetrus offers innovative solutions for pharmaceuticals, digital imaging, practice management software, and more. As a global leader in animal health, Covetrus leverages its expertise to provide high-quality care and support for companion animals, livestock, and other creatures.
The main competitors of Covetrus Inc in the market include IDEXX Laboratories, Inc., Patterson Companies, Inc., and Henry Schein, Inc.
Covetrus Inc is a leading global animal health technology and services company. It was formed in 2019 as a result of a merger between Vets First Choice and Henry Schein Animal Health. With a rich history, Covetrus has roots that date back to the mid-1990s when Vets First Choice was first established. Over the years, the company has evolved, expanded its offerings, and developed innovative solutions to support veterinary professionals and animal health. Covetrus now operates in more than 25 countries, serving over 100,000 customers worldwide. Its comprehensive portfolio includes practice management software, pharmacy services, online pharmacy platforms, and supply chain solutions, all aimed at improving the health and well-being of animals.
Covetrus Inc, a leading global animal-health technology and services company, has achieved significant milestones since its establishment. The company has successfully expanded its product portfolio, offering a comprehensive range of veterinary supplies, medications, and clinical services to support animal healthcare providers. Covetrus Inc has also implemented innovative technologies to enhance efficiency and streamline operations, driving growth and improving customer satisfaction. Additionally, the company has made strategic acquisitions and partnerships to strengthen its global presence and expand its offerings in the animal health industry. Covetrus Inc continues to demonstrate its commitment to advancing animal healthcare through continuous innovation and strategic initiatives.
Covetrus Inc is primarily present in multiple countries and regions worldwide. The company has a global reach, with a strong presence in North America, Europe, and Asia. Covetrus serves customers in the United States, Canada, the United Kingdom, Germany, France, Italy, Spain, the Netherlands, China, and several other countries. With its expansive international footprint, Covetrus aims to meet the diverse needs of veterinary practices and animal health professionals across different markets and geographies.
Covetrus Inc represents a set of core values and a strong corporate philosophy. The company is committed to providing comprehensive animal healthcare solutions with compassion and innovation. Covetrus aims to improve the well-being and longevity of animals, while supporting the success of veterinary professionals through a client-centric approach. With a focus on excellence, collaboration, and integrity, Covetrus ensures the delivery of high-quality products, services, and technology solutions to meet the evolving needs of the animal healthcare industry. The company's dedication to ethical practices and sustainability further exemplifies their commitment to both their customers and the global community.
11 analysts currently rate the Covetrus stock: 0 recommend buying, 8 holding and 3 selling.
The Covetrus share (CVET) is listed on 6 stock exchanges, including: NASDAQ (CVET), XETRA (2NJ.DE), Frankfurt (2NJ), München (2NJ.MU), Düsseldorf (2NJ.DU), London (0A0V.L).
Covetrus Inc. is a leading company in the animal health industry, offering a wide range of solutions and products used by veterinarians, animal clinics, and other companies in the animal health sector. The company was founded in February 2019 when the two companies Vets First Choice and Henry Schein Animal Health merged. Covetrus Inc. provides its customers with a comprehensive platform that allows them to run their business more effectively, increase their revenue, and better serve their customers. The platform includes a variety of tools and services, including e-commerce solutions, practice management software, customized marketing solutions, veterinary products, and more. E-commerce solutions: Covetrus Inc. provides merchants and veterinarians with a platform that enables them to sell their goods online while better serving their customers. The platform is fully customizable and can be tailored to the specific requirements of each merchant. Practice management software: Covetrus Inc. offers a wide range of solutions to help veterinarians and animal clinics operate their practice more effectively. This includes solutions such as simplifying appointment scheduling, billing, invoicing, patient and inventory management, and a variety of other tools to optimize workflow in the practice. Marketing solutions: Covetrus Inc. works closely with its customers to develop customized marketing solutions that are specifically tailored to the needs and requirements of each company. This includes solutions such as developing and implementing advertising campaigns, emails, social media marketing, and more. Veterinary products: Covetrus Inc. offers a wide range of veterinary products used by veterinarians and animal clinics. The products range from diagnostic tests to surgical instruments, providing top quality and reliability. Covetrus Inc. operates in various regions of the world, including North America, Europe, Asia, and Australasia. The company pursues a strategy of continuous improvement and innovation to constantly provide its customers with new and improved solutions. It works closely with its customers to ensure that its products and services meet their requirements and needs. Overall, Covetrus Inc. is a leading company in the animal health industry that offers its customers a wide range of solutions and products. From e-commerce solutions to veterinary products, Covetrus Inc. has an industry-leading platform that allows its customers to run their business more effectively while better serving their customers.
The revenue cannot currently be calculated for Covetrus.
The profit cannot currently be calculated for Covetrus.
The P/E ratio cannot be calculated for Covetrus at the moment.
The P/S cannot be calculated for Covetrus currently.
The Eulerpool Quality Score for Covetrus is 2/10.
The ISIN of Covetrus is US22304C1009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Covetrus is A2PBX0. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Covetrus is CVET. The ticker symbol is used to trade Covetrus shares on the stock exchange.
Covetrus is assigned to the 'Health' sector.
The dividends of Covetrus are distributed in USD.
Covetrus stock
Covetrus Peer Group
Covetrus Ticker
All fundamentals and in-depth analysis of Covetrus
Our stock analysis for Covetrus stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Covetrus. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.